1- methyl- 4- cyclohexyl- 1,2,3,6- tetrahydropyridine

04/01/2008 - "Mucinous cystic tumors (MCTP) are uncommon borderline lesions of the pancreas that may often be misdiagnosed as pseudocysts and have unknown propensity to malignity. "
01/01/2023 - "Thanks to the excellent photothermal performance of the PDA shell in the near-infrared (NIR) region, photothermal therapy (PTT) further improved the catalytic activity of Ce3+/4+. The therapeutic strategy of combining PTT, CDT, GSH-consumption and TH588-mediated amplification of DNA damage endows MCTP-FA with powerful tumor inhibition efficacy both in vitro and in vivo."
04/01/2008 - "During the last two decades in our clinic of 38 patients with cystic lesions of the pancreas two presented MCTP: a 48-year-old woman with a cyst located in the body and tail of the pancreas and a 59-year-old man with a tumor situated in the head of the gland producing an obstructive jaundice. "

07/01/1993 - "In summary, MCTP treatment of rats decreases the fibrinolytic activity of lung tissue relatively early after exposure to the toxicant and before the onset of pulmonary hypertension. "
06/15/1989 - "These results support the hypothesis that the development of MCTP-induced pulmonary hypertension is mediated in part by platelets."
01/01/1988 - "Although the mechanism by which MCTP causes pulmonary hypertension is unknown, vasoconstriction may play a role. "
04/01/1987 - "Fourteen days following treatment with MCTP when pulmonary hypertension is well-established and RVE is present, the concentration of 5HT in washed platelets or in platelet-poor plasma was not different in treated and control rats. "
01/01/1987 - "These data indicate that MCTP treatment increases the release of TxB2 from isolated lungs at a time when pulmonary hypertension is well-established, but not during early development of pulmonary hypertension."

12/01/1988 - "Data from this study support the hypothesis that platelets are involved in the development of the pulmonary hypertensive response following MCTP-induced lung injury."
07/01/1993 - "Lung injury was evident 3 days after administration of MCTP and became more pronounced with time. "
06/01/1993 - "It has been suggested that the lung injury caused by this compound may be initiated by an interaction between MCTP and cells of the pulmonary vasculature. "
06/15/1989 - "When rats were treated similarly with MCTP and PAS and were killed at 18 days, the attenuation of the pulmonary hypertensive response previously described was not observed, and lung injury was more extensive than when CS was given. "
12/01/1988 - "A higher dose of MCTP (35 mg/kg) caused moderate lung injury at 6 hr. However, this treatment did not result in increased platelet sequestration in the lungs, although a trend was observed. "

04/28/1998 - "In the setting of MCTP-induced CPH, significant worsening of RV diastolic function was observed in association with significant increases in the ratio of RV dry weight to LV+septal dry weight, suggesting that these changes are partially due to RV hypertrophy. "
03/01/1997 - "MCTP caused increased LDH release by 48 hr, augmented PGI2 synthesis by 96 hr, and resulted in hypertrophy and decreased cell density by 48 hr that persisted at least 21 days. "
06/01/1994 - "At Day 14 only, the hearts of MCTP-treated rats appeared enlarged and there was right cardioventricular hypertrophy. "
07/01/1991 - "Right cardioventricular hypertrophy was first detected at 8 days in MCTP-treated rats and became more pronounced with time. "
03/01/1991 - "Progressive and marked endothelial cell hypertrophy occurred after exposure to a nominal concentration of 5 or 50 micrograms/ml of MCTP but not after 0.5 micrograms/ml. Morphologic changes in monolayers of BSMCs were minimal, even up to 2 weeks after exposure. "

01/26/1996 - "The monocrotaline pyrrole (MCTP)-treated rat is a useful model for the study of certain chronic pulmonary vascular diseases. "